Vir Biotechnology Q2 EPS $(1.45) Misses $(1.20) Estimate, Sales $3.80M Miss $25.89M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology reported Q2 losses of $(1.45) per share, missing the analyst consensus estimate of $(1.20) by 20.83%. This is a 150% increase in losses from the same period last year. The company also reported quarterly sales of $3.80 million, missing the analyst consensus estimate of $25.89 million by 85.33%. This is a 109.35% increase over sales from the same period last year.
August 04, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology's Q2 results missed analyst estimates, with a significant increase in losses and lower than expected sales.
The company reported higher than expected losses and lower than expected sales for Q2. This negative financial performance is likely to negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100